ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer April 14, 2022
Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines April 14, 2022
Be Bio Appoints Leading Cell & Gene Therapy Executives, Krishnan Viswanadhan as President & Chief Operating Officer, and Brad Hartman as Chief People Officer August 12, 2021
